Evolving Treatment Strategies for R/R Follicular Lymphoma

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana LLC.

Viviana Cortiana, MS4;Yan Leyfman, MD

FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

$In lieu of an 8-to-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.$

Highlighting Insights From the Marginal Zone Lymphoma Workshop

In lieu of an 8-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Russ Conroy

FDA Removes REMS, Lessens Requirements of Liso-Cel/Ide-Cel in Blood Cancers

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Related Content

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana LLC.

Viviana Cortiana, MS4;Yan Leyfman, MD

FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

$In lieu of an 8-to-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.$

Highlighting Insights From the Marginal Zone Lymphoma Workshop

In lieu of an 8-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Russ Conroy

FDA Removes REMS, Lessens Requirements of Liso-Cel/Ide-Cel in Blood Cancers

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.